Does the media favor ADMA or LGND?

In the previous week, ADMA Biologics had 7 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 10 mentions for ADMA Biologics and 3 mentions for Ligand Pharmaceuticals. ADMA Biologics' average media sentiment score of 1.08 beat Ligand Pharmaceuticals' score of 0.51 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LGND or ANIP?

In the previous week, ANI Pharmaceuticals had 4 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 7 mentions for ANI Pharmaceuticals and 3 mentions for Ligand Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.02 beat Ligand Pharmaceuticals' score of 0.51 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor UTHR or LGND?

In the previous week, United Therapeutics had 21 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 24 mentions for United Therapeutics and 3 mentions for Ligand Pharmaceuticals. United Therapeutics' average media sentiment score of 0.92 beat Ligand Pharmaceuticals' score of 0.51 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 12 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LGND or GMAB?

In the previous week, Ligand Pharmaceuticals had 1 more articles in the media than Genmab A/S. MarketBeat recorded 3 mentions for Ligand Pharmaceuticals and 2 mentions for Genmab A/S. Ligand Pharmaceuticals' average media sentiment score of 0.51 beat Genmab A/S's score of 0.25 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ASND or LGND?

In the previous week, Ascendis Pharma A/S had 31 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 34 mentions for Ascendis Pharma A/S and 3 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.51 beat Ascendis Pharma A/S's score of 0.37 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 8 Very Positive mention(s) 10 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ligand Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ligand Pharmaceuticals (LGND) Competitors

$285.60 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Compare

LGND vs. ADMA, ANIP, UTHR, GMAB, and ASND

Should you buy Ligand Pharmaceuticals stock or one of its competitors? Ligand Pharmaceuticals's main competitors and comparable companies include ADMA Biologics (ADMA), ANI Pharmaceuticals (ANIP), United Therapeutics (UTHR), Genmab A/S (GMAB), and Ascendis Pharma A/S (ASND). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Ligand Pharmaceuticals compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Ligand Pharmaceuticals (NASDAQ:LGND) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, ADMA Biologics had 7 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 10 mentions for ADMA Biologics and 3 mentions for Ligand Pharmaceuticals. ADMA Biologics' average media sentiment score of 1.08 beat Ligand Pharmaceuticals' score of 0.51 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ADMA Biologics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

ADMA Biologics currently has a consensus target price of $18.67, suggesting a potential upside of 94.04%. Ligand Pharmaceuticals has a consensus target price of $335.75, suggesting a potential upside of 17.56%. Given ADMA Biologics' higher possible upside, research analysts clearly believe ADMA Biologics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00

Ligand Pharmaceuticals has a net margin of 67.88% compared to ADMA Biologics' net margin of 32.98%. ADMA Biologics' return on equity of 40.17% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Ligand Pharmaceuticals	67.88%	20.06%	11.68%

ADMA Biologics has higher revenue and earnings than Ligand Pharmaceuticals. ADMA Biologics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.22	$146.93M	$0.70	13.74
Ligand Pharmaceuticals	$268.09M	21.24	$124.45M	$9.35	30.55

Summary

Ligand Pharmaceuticals beats ADMA Biologics on 9 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Ligand Pharmaceuticals has a net margin of 67.88% compared to ANI Pharmaceuticals' net margin of 11.07%. ANI Pharmaceuticals' return on equity of 27.37% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

Ligand Pharmaceuticals has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

Ligand Pharmaceuticals has higher earnings, but lower revenue than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	21.24	$124.45M	$9.35	30.55
ANI Pharmaceuticals	$883.37M	1.85	$78.34M	$4.64	15.35

In the previous week, ANI Pharmaceuticals had 4 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 7 mentions for ANI Pharmaceuticals and 3 mentions for Ligand Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.02 beat Ligand Pharmaceuticals' score of 0.51 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ANI Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Ligand Pharmaceuticals presently has a consensus price target of $335.75, suggesting a potential upside of 17.56%. ANI Pharmaceuticals has a consensus price target of $105.83, suggesting a potential upside of 48.58%. Given ANI Pharmaceuticals' higher probable upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Ligand Pharmaceuticals beats ANI Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Ligand Pharmaceuticals has a net margin of 67.88% compared to United Therapeutics' net margin of 41.56%. United Therapeutics' return on equity of 20.18% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Ligand Pharmaceuticals	67.88%	20.06%	11.68%

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 8.6% of United Therapeutics shares are held by company insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

United Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

In the previous week, United Therapeutics had 21 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 24 mentions for United Therapeutics and 3 mentions for Ligand Pharmaceuticals. United Therapeutics' average media sentiment score of 0.92 beat Ligand Pharmaceuticals' score of 0.51 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	12 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics presently has a consensus target price of $646.00, suggesting a potential upside of 32.48%. Ligand Pharmaceuticals has a consensus target price of $335.75, suggesting a potential upside of 17.56%. Given United Therapeutics' higher possible upside, equities analysts clearly believe United Therapeutics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00

United Therapeutics has higher revenue and earnings than Ligand Pharmaceuticals. United Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	6.57	$1.33B	$27.95	17.45
Ligand Pharmaceuticals	$268.09M	21.24	$124.45M	$9.35	30.55

Summary

United Therapeutics beats Ligand Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to Genmab A/S?

Ligand Pharmaceuticals (NASDAQ:LGND) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Ligand Pharmaceuticals has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 5.6% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Ligand Pharmaceuticals has a net margin of 67.88% compared to Genmab A/S's net margin of 19.08%. Ligand Pharmaceuticals' return on equity of 20.06% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
Genmab A/S	19.08%	14.89%	7.73%

Genmab A/S has higher revenue and earnings than Ligand Pharmaceuticals. Genmab A/S is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	21.24	$124.45M	$9.35	30.55
Genmab A/S	$3.72B	5.63	$963M	$1.27	26.46

Ligand Pharmaceuticals currently has a consensus target price of $335.75, indicating a potential upside of 17.56%. Genmab A/S has a consensus target price of $39.50, indicating a potential upside of 17.56%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

In the previous week, Ligand Pharmaceuticals had 1 more articles in the media than Genmab A/S. MarketBeat recorded 3 mentions for Ligand Pharmaceuticals and 2 mentions for Genmab A/S. Ligand Pharmaceuticals' average media sentiment score of 0.51 beat Genmab A/S's score of 0.25 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ligand Pharmaceuticals beats Genmab A/S on 12 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ascendis Pharma A/S currently has a consensus price target of $310.05, indicating a potential upside of 14.60%. Ligand Pharmaceuticals has a consensus price target of $335.75, indicating a potential upside of 17.56%. Given Ligand Pharmaceuticals' higher probable upside, analysts clearly believe Ligand Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.05
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00

Ascendis Pharma A/S has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

Ascendis Pharma A/S has a net margin of 70.99% compared to Ligand Pharmaceuticals' net margin of 67.88%. Ascendis Pharma A/S's return on equity of 32.54% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Ligand Pharmaceuticals	67.88%	20.06%	11.68%

In the previous week, Ascendis Pharma A/S had 31 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 34 mentions for Ascendis Pharma A/S and 3 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.51 beat Ascendis Pharma A/S's score of 0.37 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	8 Very Positive mention(s)	10 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ligand Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	20.72	-$258M	$12.89	20.99
Ligand Pharmaceuticals	$268.09M	21.24	$124.45M	$9.35	30.55

Summary

Ascendis Pharma A/S beats Ligand Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Ligand Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LGND vs. The Competition

Export

Metric	Ligand Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.69B	$4.00B	$7.21B	$12.89B
Dividend Yield	N/A	3.60%	2.54%	9.13%
P/E Ratio	30.55	12.71	273.81	25.45
Price / Sales	21.24	1,346.44	625.31	100.42
Price / Cash	36.37	45.00	28.92	35.62
Price / Book	5.53	16.40	11.01	6.39
Net Income	$124.45M	-$22.85M	$3.49B	$358.69M
7 Day Performance	0.53%	1.39%	1.64%	0.22%
1 Month Performance	-2.58%	5.96%	4.43%	-0.10%
1 Year Performance	71.27%	49.25%	24.20%	14.04%

Ligand Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LGND Ligand Pharmaceuticals	3.6993 of 5 stars	$285.60 flat	$335.75 +17.6%	+71.3%	$5.69B	$268.09M	30.55	80
ADMA ADMA Biologics	3.8362 of 5 stars	$9.34 -1.5%	$18.67 +99.9%	-43.0%	$2.09B	$510.17M	13.34	530	Positive News
ANIP ANI Pharmaceuticals	3.8926 of 5 stars	$72.83 -0.9%	$105.83 +45.3%	-25.3%	$1.67B	$978.38M	15.70	600	Positive News
UTHR United Therapeutics	4.6626 of 5 stars	$515.46 -2.4%	$646.00 +25.3%	+21.7%	$22.11B	$3.18B	18.44	1,400	Trending News
GMAB Genmab A/S	3.5585 of 5 stars	$33.23 -2.6%	$39.50 +18.9%	+22.0%	$20.72B	$3.72B	26.17	3,029	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LGND) was last updated on 9/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ligand Pharmaceuticals (LGND) Competitors

LGND vs. ADMA, ANIP, UTHR, GMAB, and ASND

How does Ligand Pharmaceuticals compare to ADMA Biologics?

Summary

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

Summary

How does Ligand Pharmaceuticals compare to United Therapeutics?

Summary

How does Ligand Pharmaceuticals compare to Genmab A/S?

Summary

How does Ligand Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGND vs. The Competition

Ligand Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ligand Pharmaceuticals (LGND) Competitors

LGND vs. ADMA, ANIP, UTHR, GMAB, and ASND

How does Ligand Pharmaceuticals compare to ADMA Biologics?

Do institutionals & insiders hold more shares of ADMA or LGND?

Does the media favor ADMA or LGND?

Which has more risk & volatility, ADMA or LGND?

Do analysts recommend ADMA or LGND?

Is ADMA or LGND more profitable?

Which has higher valuation and earnings, ADMA or LGND?

Summary

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

Is LGND or ANIP more profitable?

Which has more risk & volatility, LGND or ANIP?

Which has higher valuation & earnings, LGND or ANIP?

Does the media prefer LGND or ANIP?

Do institutionals and insiders hold more shares of LGND or ANIP?

Do analysts rate LGND or ANIP?

Summary

How does Ligand Pharmaceuticals compare to United Therapeutics?

Is UTHR or LGND more profitable?

Do insiders & institutionals hold more shares of UTHR or LGND?

Which has more risk and volatility, UTHR or LGND?

Does the media favor UTHR or LGND?

Do analysts rate UTHR or LGND?

Which has stronger earnings & valuation, UTHR or LGND?

Summary

How does Ligand Pharmaceuticals compare to Genmab A/S?

Which has more volatility & risk, LGND or GMAB?

Do institutionals & insiders have more ownership in LGND or GMAB?

Is LGND or GMAB more profitable?

Which has better valuation & earnings, LGND or GMAB?

Do analysts recommend LGND or GMAB?

Does the media prefer LGND or GMAB?

Summary

How does Ligand Pharmaceuticals compare to Ascendis Pharma A/S?

Do institutionals and insiders have more ownership in ASND or LGND?

Do analysts recommend ASND or LGND?

Which has more volatility and risk, ASND or LGND?

Is ASND or LGND more profitable?

Does the media refer more to ASND or LGND?

Which has stronger earnings and valuation, ASND or LGND?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGND vs. The Competition

Ligand Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools